Prosthetic Valve

TAVR using the self-expanding valve Evolut FX for Aortic Valve Stenosis

N/A
Waitlist Available
Led By Sadeer Al-Kindi, MD
Research Sponsored by Guilherme Attizzani, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up1-year
Awards & highlights
No Placebo-Only Group

Study Summary

This trial aims to compare 2 types of mitral valve replacement, SEV & BEV, to see which is better in terms of blood flow & exercise capacity, using CMR for a more precise assessment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Effective orifice area (EOA)
Mean gradient
Peak gradient
Secondary outcome measures
Morbidity - disease rate
EOA by echo
Echotomography, Computer
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: TAVR using the self-expanding valve Evolut FXActive Control1 Intervention
Transcatheter aortic valve replacement (TAVR) using the bioprosthesis Medtronic Evolut FX supra-annular self-expanding valve
Group II: TAVR using the balloon-expandable valve Sapien 3 UltraActive Control1 Intervention
Transcatheter aortic valve replacement (TAVR) using the bioprosthesis Edwards Sapien 3 Ultra valve

Find a site

Who is running the clinical trial?

Guilherme Attizzani, MDLead Sponsor
Sadeer Al-Kindi, MDPrincipal Investigator
University Hospitals Cleveland Medical Center
2 Previous Clinical Trials
7,013 Total Patients Enrolled

Media Library

Balloon-expanding valve (Edwards Sapien 3 Ultra) (Prosthetic Valve) Clinical Trial Eligibility Overview. Trial Name: NCT05603026 — N/A
Aortic Valve Stenosis Research Study Groups: TAVR using the self-expanding valve Evolut FX, TAVR using the balloon-expandable valve Sapien 3 Ultra
Aortic Valve Stenosis Clinical Trial 2023: Balloon-expanding valve (Edwards Sapien 3 Ultra) Highlights & Side Effects. Trial Name: NCT05603026 — N/A
Balloon-expanding valve (Edwards Sapien 3 Ultra) (Prosthetic Valve) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05603026 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the research team seeking out participants of a certain age for this clinical trial?

"The eligibility requirements of this trial are such that participants must be 18 to 105 years old. Separately, there exist 24 trials for minors and 161 studies specifically targeting seniors."

Answered by AI

What impact is this medical experiment expected to produce?

"Over the course of a year, this study will seek to measure peak gradient as its primary objective. Secondary outcomes include exercise capacity post TAVR assessed by CMR (METs), left ventricle ejection fraction measured with transthoracic echocardiography (%), and mean gradient evaluated through transthoracic echocardiography (mmHg)."

Answered by AI

Who qualifies as an eligible participant for this research study?

"Qualified candidates for this clinical trial must have aortic valve stenosis and be within the age bracket of 18-105. The research is looking to enrol 90 people in total."

Answered by AI

Are there any vacancies for participants yet in this experiment?

"According to clinicaltrials.gov, this experiment is not currently taking on any new participants. The trial was originally posted January 1st 2023 and last edited November 1st 2022. Although it has closed its doors for recruitment, there are 161 other medical tests actively searching for volunteers as we speak."

Answered by AI
~60 spots leftby Dec 2024